Insider Selling: Quest Diagnostics Inc (DGX) SVP Sells 40,328 Shares of Stock

Quest Diagnostics Inc (NYSE:DGX) SVP Everett Cunningham sold 40,328 shares of Quest Diagnostics stock in a transaction that occurred on Tuesday, July 10th. The shares were sold at an average price of $112.00, for a total transaction of $4,516,736.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Everett Cunningham also recently made the following trade(s):

  • On Monday, July 2nd, Everett Cunningham sold 68,069 shares of Quest Diagnostics stock. The shares were sold at an average price of $109.67, for a total transaction of $7,465,127.23.

Shares of DGX stock traded up $0.32 during trading on Thursday, reaching $113.90. The company’s stock had a trading volume of 820,154 shares, compared to its average volume of 993,114. The company has a quick ratio of 1.14, a current ratio of 1.23 and a debt-to-equity ratio of 0.73. Quest Diagnostics Inc has a one year low of $90.10 and a one year high of $116.49. The firm has a market cap of $15.35 billion, a PE ratio of 21.11, a P/E/G ratio of 2.23 and a beta of 0.69.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Thursday, April 19th. The medical research company reported $1.52 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.52. Quest Diagnostics had a net margin of 10.19% and a return on equity of 15.44%. The firm had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same period in the prior year, the firm posted $1.33 earnings per share. The company’s quarterly revenue was up 3.7% compared to the same quarter last year. equities analysts predict that Quest Diagnostics Inc will post 6.61 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, July 23rd. Shareholders of record on Monday, July 9th will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.76%. The ex-dividend date of this dividend is Friday, July 6th. Quest Diagnostics’s dividend payout ratio (DPR) is currently 37.04%.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. raised its position in Quest Diagnostics by 7.4% during the first quarter. BlackRock Inc. now owns 15,582,475 shares of the medical research company’s stock worth $1,562,924,000 after acquiring an additional 1,071,083 shares in the last quarter. Fiduciary Management Inc. WI raised its position in Quest Diagnostics by 76.5% during the first quarter. Fiduciary Management Inc. WI now owns 3,669,715 shares of the medical research company’s stock worth $368,072,000 after acquiring an additional 1,590,069 shares in the last quarter. American Century Companies Inc. raised its position in Quest Diagnostics by 16.4% during the first quarter. American Century Companies Inc. now owns 2,372,859 shares of the medical research company’s stock worth $237,998,000 after acquiring an additional 333,749 shares in the last quarter. Allianz Asset Management GmbH raised its position in Quest Diagnostics by 8.3% during the first quarter. Allianz Asset Management GmbH now owns 2,326,398 shares of the medical research company’s stock worth $233,338,000 after acquiring an additional 178,041 shares in the last quarter. Finally, Summit Trail Advisors LLC raised its position in Quest Diagnostics by 11,477.8% during the first quarter. Summit Trail Advisors LLC now owns 1,769,084 shares of the medical research company’s stock worth $1,769,000 after acquiring an additional 1,753,804 shares in the last quarter. 87.40% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have weighed in on DGX. Barclays raised shares of Quest Diagnostics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $120.00 to $130.00 in a research note on Monday, June 25th. ValuEngine lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Monday, April 2nd. Zacks Investment Research raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $115.00 price target on the stock in a research note on Tuesday, May 22nd. Robert W. Baird raised shares of Quest Diagnostics from a “neutral” rating to an “outperform” rating and set a $115.00 price target on the stock in a research note on Tuesday, May 1st. Finally, Morgan Stanley raised shares of Quest Diagnostics from an “underweight” rating to an “equal weight” rating and set a $103.00 price target on the stock in a research note on Wednesday, March 14th. Thirteen equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $110.44.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Insider Buying and Selling by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply